Cervical Carcinoma Presentation (PATH 752)

62
Presented By: L. Luketic

description

PATH 752 Presentation on Cervical Carcinoma, including 10 summary questions and answers

Transcript of Cervical Carcinoma Presentation (PATH 752)

Page 1: Cervical Carcinoma Presentation (PATH 752)

Presented By: L. Luketic

Page 2: Cervical Carcinoma Presentation (PATH 752)

Definitions: Cervical Dysplasia: is abnormal cell growth

on the surface lining of the cervix, which may progress to cervical cancer

Cervical Cancer: cancer that arises in the tissues of the uterine cervix

Pap (Papanicolaou) Smear/Test: is a cytologic exfoliative screening test

Intraepithelial: is the layer of cells that forms the surface of the cervix

Page 3: Cervical Carcinoma Presentation (PATH 752)

Definitions Continued: Koilocytic atypia: are nuclear alterations and is a

cytoplasmic perinuclear halo

Microinvasive Carcinoma: stromal invasion of the cervical epithelium does not extend deeper than 3mm and is not wider than 7mm

Carcinoma in situ: a group of abnormal cells that have not spread, but may progress to invasive cancer

Colposcopy: a procedure that uses a lighted magnifying tool (colposcope), allowing the doctor to take a closer look at the cervix and vagina

Page 4: Cervical Carcinoma Presentation (PATH 752)

Cervical SCJ & T zone: Squamocolumnar Junction (SCJ):

Non-keratinized stratified Squamous epithelium (ectocervix) Non-ciliated simple columnar epithelium (endocervix)

Transformation Zone (T zone):Original SCJ New SCJ

Clinical significance of the SCJ:Almost ALL primary cervical carcinomas arise

in this region of the cervix

Page 5: Cervical Carcinoma Presentation (PATH 752)

Cervical Squamocolumar Junction: (Robbins Fig. 22-16)

Page 6: Cervical Carcinoma Presentation (PATH 752)

Cervical SCJ & T zone Grossly:

Merck & Co., Inc. Human Papillomavirus, Monographs in Medicine. Whitehouse Station, NJ: Merck and Co; 2008.

Page 7: Cervical Carcinoma Presentation (PATH 752)

SCJ & T zone Histologically:

http://1.bp.blogspot.com/_OwoEg7Db_AE/TQTYcJz2cTI/AAAAAAAAA9o/Q5neoLm6-CQ/s1600/CTZ%2Bb.png

Page 8: Cervical Carcinoma Presentation (PATH 752)

Incidence & Mortality Rate of Cervical Carcinomas: According to the National Cancer

Institute, estimated new cases and deaths from cervical (uterine cervix) cancer in the U.S. in 2013 are:New cases: 12,340Deaths: 4,030

Worldwide, cervical carcinoma is the second most common cancer in women

Page 9: Cervical Carcinoma Presentation (PATH 752)

Pathogenesis of Cervical Neoplasia: Most HPV infections are eliminated by our

immune system

HPV infects immature squamous epithelial cells

HPV replicates in maturing squamous cells koilocytic atypia

HPV activates the cell cycle by interfering with the function of Rb and p53

Page 10: Cervical Carcinoma Presentation (PATH 752)

Pathogenesis of Cervical Neoplasia Continued: E6 HPV oncoprotein binds to p53 interrupted

apoptosis of genetically altered cell

E7 HPV oncoprotein binds to RB promotes cell growth and up regulation of cyclin E (E7)

Together E6 & E7 induce centrosome duplication and genomic instability

Factors other than HPV also play a role in cervical carcinoma

Page 11: Cervical Carcinoma Presentation (PATH 752)

http://www.nature.com/nrc/journal/v7/n1/fig_tab/nrc2050_F1.html

Page 12: Cervical Carcinoma Presentation (PATH 752)

Roden and Wu Nature Reviews Cancer 6, 753–763 (October 2006) | doi:10.1038/nrc1973

Page 13: Cervical Carcinoma Presentation (PATH 752)

Risk Factors for Cervical Cancer: Persistent infection with a high oncogenic

risk HPV, e.g., HPV 16 or HPV 18 Multiple sexual partners A male partner with multiple previous or

current sexual partners Young age at first intercourse High parity Immunosuppression Age Use of oral contraceptives Use of nicotine/smoking

Page 14: Cervical Carcinoma Presentation (PATH 752)

Human Papillomavirus (HPV): “HPV is the most common viral STI in the U.S.”

Harald zur Hausen: discovered that HPV is a major cause of cervical carcinoma

2 Classifications of HPV Infection:Low oncogenic risk HPVs: (6, 11, …)High oncogenic risk HPVs: (16, 18, 31, 33, …)

The most significant factor in cervical oncogenesis is said to be “High Oncogenic risk HPVs”

Page 15: Cervical Carcinoma Presentation (PATH 752)

ROBBINS TABLE 22-1

Page 16: Cervical Carcinoma Presentation (PATH 752)

Cervical Intraepithelial Neoplasia (CIN): Precursor to Cervical SCC

Neoplastic changes of the ectocervical squamous epithelium

CIN I: caused by low oncogenic risk HPVsMild koilocytic atypia

CIN II: caused by high oncogenic risk HPVsModerate koilocytic atypia of the squamous cells

CIN III: caused by high oncogenic risk HPVsSevere koilocytic atypia of immature squamous cells

Page 17: Cervical Carcinoma Presentation (PATH 752)

Cervical Cancer Histology: Robbins Fig. 22-17Normal CIN I CIN II CIN III

Page 18: Cervical Carcinoma Presentation (PATH 752)

The cytology of a CIN seen on a Pap smear (Robbins Fig. 22-21)

Page 19: Cervical Carcinoma Presentation (PATH 752)

The Bethesda System: (LSIL) Low-grade Intraepithelial Lesions (LSIL):

Mild dysplasia

Do NOT directly progress to invasive carcinoma

HPV 6 & 11 cause ~90% of all condylomata acuminata

Koilocytic atypia of immature squamous cells = remains in the lower 1/3rd of epithelium

Page 20: Cervical Carcinoma Presentation (PATH 752)

The Bethesda System: (HSIL) High-grade Intraepithelial Lesions (HSIL):

Moderate to severe dysplasia

Pre-cancerous lesions

HPV types 16 & 18 have the highest correlation of causing cervical cancer○ HPV types 31 & 33 also have a high correlation of

causing cervical cancer

Koilocytic atypia of immature squamous cells = extends to 2/3rds of epithelial thickness

Page 21: Cervical Carcinoma Presentation (PATH 752)

HPV Groups/Types:

Expert Rev Mol Diagn. 2008;8(4):405-415. © 2008  Expert Reviews Ltd. http://www.medscape.com/viewarticle/585223

Page 22: Cervical Carcinoma Presentation (PATH 752)

Cervical Cancer Histology: (Robbins Fig. 22-18) LSIL – stained with multiple techniques

Ki-67 & p16 are used to confirm SIL diagnosis

Page 23: Cervical Carcinoma Presentation (PATH 752)
Page 24: Cervical Carcinoma Presentation (PATH 752)

ROBBINS TABLE 22-2

Page 25: Cervical Carcinoma Presentation (PATH 752)

Normal Cervix (Gross):

http://library.med.utah.edu/WebPath/jpeg4/FEM002.jpg

Page 26: Cervical Carcinoma Presentation (PATH 752)

Invasive Carcinoma of the Cervix Tumor extension is by direct MET,

involving adjacent tissues which can include:Paracervical tissuesUrinary bladderUretersRectumVagina

Local and distant lymph node METs Distant METs (liver, lungs, bone marrow,

other)

Page 27: Cervical Carcinoma Presentation (PATH 752)

4 Main Types of Primary Cervical Cancer: Squamous cell carcinoma (SCC) = most

common

Adenocarcinoma = 2nd most common

Adenosquamous carcinoma (or Mixed Cell Carcinomas)

Neuroendocrine (oat cell) carcinoma (NEC)

Page 28: Cervical Carcinoma Presentation (PATH 752)

SCC of the Uterine Cervix: SCCs most often arise at the SCJ Grossly: (3 forms)

Fungating (exophytic) or infiltrativeUlceratedInvasive lesion that causes induration or other

deformities of the cervix Histologically:

Nests and tongues of malignant cellsKeratinizing or Non-keratinizing

Clinical Symptoms:Early-stage: may be asymptomaticLater-stage: abnormal vaginal bleeding, increased

vaginal discharge, pelvic pain, or pain during intercourse

Page 29: Cervical Carcinoma Presentation (PATH 752)

Gross Cervical SCC: (Stage 1)

http://library.med.utah.edu/WebPath/FEMHTML/FEMIDX.html#2

Page 30: Cervical Carcinoma Presentation (PATH 752)

Cervical SCC (Gross) Extensive:

http://library.med.utah.edu/WebPath/FEMHTML/FEMIDX.html

Page 31: Cervical Carcinoma Presentation (PATH 752)

SCC of the Cervix (Robbins Fig. 22-19)

Page 32: Cervical Carcinoma Presentation (PATH 752)

Cervical Adenocarcinomas: Arise in the columnar epithelium (glandular cells that

produce mucus) of the endocervix Grossly:

Fungating (exophytic)InfiltrativeAbnormal mass/growth visible during colposcopy

Histologically: Glandular epithelium proliferation of malignant endocervical

cellsLarge hyperchromatic nucleiCytoplasm is mostly depleted of mucin

Clinical Symptoms: Abnormal vaginal bleeding/discharge, pelvic pain, or

asymptomatic

Page 33: Cervical Carcinoma Presentation (PATH 752)

Cervical Adenocarcinoma (Gross):

http://www.askjpc.org/wsco/wsc_showconference.php?id=294

Page 34: Cervical Carcinoma Presentation (PATH 752)

Adenocarcinoma of the Cervix (Robbins Fig. 22-20)

Page 35: Cervical Carcinoma Presentation (PATH 752)

Staging of Cervical Carcinoma (Robbins)

http://www.studentconsult.com/content/default.cfm?ISBN=9781416031215

Page 36: Cervical Carcinoma Presentation (PATH 752)

Prognosis:

5-year survival rates:Stage Ia = ~95%Stage Ib = ~80-90%Stage II = ~75%Stage III+ = <50%

Stage IV most common cause of death is local extension

The prognosis of adenosquamous and neuroendocrine carcinomas are worse than adenocarcinomas and SCCs

Page 37: Cervical Carcinoma Presentation (PATH 752)

Cervical Screening: Pap smears are the most efficient way to

test for/diagnose pre-invasive and invasive cervical carcinomasStudies show that there is an ~80% decrease in

cervical cancer (incidence & mortality rate) for women that get regular Pap smears○ Cervical SCC vs. Adenocarcinoma Pap smear accuracy

HPV DNA Testing: Similar to the Pap test, HPV DNA testing uses

cervical cells for lab testingDetermines positive/negative infection for HPV

strands most likely to cause cervical carcinoma Sensitivity vs. Specificity

Page 38: Cervical Carcinoma Presentation (PATH 752)

Prevention: Vaccines: Gardasil and Cervarix

Cervarix protects against HPV 16 & 18 (High oncogenic risk HPVs ~70%)

Gardasil protects against HPV 16 & 18 (High oncogenic risk HPVs ~70%) and HPV 6 & 11 (Low oncogenic risk HPVs ~90%)

Avoid smoking Remain abstinent Delay first intercourse Use a condom during intercourse Have fewer sexual partners

Page 39: Cervical Carcinoma Presentation (PATH 752)

Treatment Options:

Pre-malignant Lesions:Surgical ConizationCryosurgeryLaser surgeryLEEP (Loop Electrosurgical Excision Procedure)

Malignant Lesions:Surgery (i.e., hysterectomy/TAHBSO)Radiation TherapyChemotherapy

Page 40: Cervical Carcinoma Presentation (PATH 752)

Review

Page 41: Cervical Carcinoma Presentation (PATH 752)

Question # 1:

What is KOILOCYTIC ATYPIA?

Page 42: Cervical Carcinoma Presentation (PATH 752)

Answer to Question #1

Nuclear alterations and a cytoplasmic perinuclear halo

Commonly seen in dysplastic cells infected with HPV

Page 43: Cervical Carcinoma Presentation (PATH 752)

Question #2:

What region of the cervix do almost ALL cervical carcinomas arise?

Page 44: Cervical Carcinoma Presentation (PATH 752)

Answer to Question #2

Squamocolumnar Junction (SCJ)

Page 45: Cervical Carcinoma Presentation (PATH 752)

Question #3: Worldwide, how does cervical carcinoma

rank compared to other cancers in women?

Page 46: Cervical Carcinoma Presentation (PATH 752)

Answer to Question #3

2nd most common

Page 47: Cervical Carcinoma Presentation (PATH 752)

Question #4:

What is said to be the MOST significant risk factor in cervical oncogenesis?

Page 48: Cervical Carcinoma Presentation (PATH 752)

Answer to Question #4

High oncogenic risk HPV infections

Page 49: Cervical Carcinoma Presentation (PATH 752)

Question # 5:

What does CIN stand for, what are the subtypes, and what is the clinical significance?

Page 50: Cervical Carcinoma Presentation (PATH 752)

Answer to Question #5

Cervical Intraepithelial Neoplasia (CIN)I: Mild dysplasiaII: Moderate dysplasiaIII: Severe dysplasiaIII: Carcinoma in situ

Precursor to cervical cancer

Page 51: Cervical Carcinoma Presentation (PATH 752)

Question # 6:

What do LSIL and HSIL stand for and which main virus strands cause them?

Page 52: Cervical Carcinoma Presentation (PATH 752)

Answer to Question #6

Low-grade Squamous Intraepithelial LesionHPV 6 & 11

High-grade Squamous Intraepithelial LesionHPV 16 & 18

Page 53: Cervical Carcinoma Presentation (PATH 752)

Question # 7:

What are the 4 main types of primary cervical carcinoma (most common least common)?

Page 54: Cervical Carcinoma Presentation (PATH 752)

Answer to Question #7

Squamous Cell Carcinoma Adenocarcinoma Adenosquamous Carcinoma Neuroendocrine Carcinoma

Page 55: Cervical Carcinoma Presentation (PATH 752)

Question # 8:

What is the most efficient way to test for/diagnose pre-invasive/invasive cervical carcinoma?

Page 56: Cervical Carcinoma Presentation (PATH 752)

Answer to Question #8

Pap smear

Page 57: Cervical Carcinoma Presentation (PATH 752)

Question # 9:

What is the percent of decrease in incidence and mortality rate, in women that get regular Pap smears?

Page 58: Cervical Carcinoma Presentation (PATH 752)

Answer to Question #9

~80% decrease in cervical cancer (incidence & mortality rate) for women that get regular Pap smears

Page 59: Cervical Carcinoma Presentation (PATH 752)

Question # 10:

What are the 2 vaccines that prevent HPV, and what are the main strands they prevent?

Page 60: Cervical Carcinoma Presentation (PATH 752)

Answer to Question #10

Cervarix protects against:HPV 16 & 18 (High oncogenic risk HPVs

~70%)

Gardasil protects against: HPV 16 & 18 (High oncogenic risk HPVs

~70%)HPV 6 & 11 (Low oncogenic risk HPVs

~90%)

Page 61: Cervical Carcinoma Presentation (PATH 752)

References: Agnes Kathrine Lie, MD, PhD, Gunnar Kristensen, MD, PhD. Human Papillomavirus

E6/E7 mRNA Testing as a Predictive Marker for Cervical Carcinoma. Expert Rev Mol Diagn. 2008;8(4):405-415.  Accessed <07/06/2013>.

"Cervical Cancer." American Cancer Society. American Cancer Society, 11 Apr. 2013. Web. 6 July 2013. <http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-what-is-cervical-cancer?sitearea=cri>.

Ciaran B. J. Woodman, Stuart I. Collins & Lawrence S. Young. The natural history of cervical HPV infection: unresolved issues. Nature Reviews Cancer 7, 11-

22 (January 2007). doi:10.1038/nrc2050

Damjanov, Ivan. Pathology Secrets. 3rd ed. Philadelphia: Saunders Elsevier, 2009. 342-44. Print.

Expert Rev Mol Diagn. 2008;8(4):405-415. © 2008  Expert Reviews Ltd. http://www.medscape.com/viewarticle/585223

http://screening.iarc.fr/atlasglossdef.php

http://www.askjpc.org/wsco/wsc_showconference.php?id=294

Page 62: Cervical Carcinoma Presentation (PATH 752)

References Continued: http://www.cap.org

http://www.mayoclinic.com/print/cervical-cancer/DS00167/DSECTION=all&METHOD=print

http://www.prn.org/index.php/coinfections/articleanogenital_hpv_neoplasia_hiv_positive_502

Kumar, Vinay, Abul Abbas, Nelson Fausto, and Jon Aster. Robbins and Cotran: Pathologic Basis of Disease. 8th ed. Philadelphia: Saunders Elsevier, 2010. 1017-24. Print.

National Cancer Institute: PDQ® Cervical Cancer Treatment. Bethesda, MD: National Cancer Institute. Date last modified <05/15/2013>. Available at: http://cancer.gov/cancertopics/pdq/treatment/cervical/HealthProfessional. Accessed <07/06/2013>.

Richard Roden & T.-C. Wu. How will HPV vaccines affect cervical cancer? Nature Reviews Cancer. 6, 753-763 (October 2006). doi:10.1038/nrc1973